Lupus & antiphospholipid syndrome
The estimated prevalence of antiphospholipid antibodies and criteria-antiphospholipid syndrome in subjects with renal thrombotic microangiopathy
Authors' conclusion
This comprehensive systematic analysis of studies investigating the prevalence of aPL in renal TMA showed that, despite the high heterogeneity of the included studies, aPL are present in about one case out of four renal-TMA cases.
Study context
- Population
- Subjects with biopsy-proven renal Thrombotic Microangiopathy (TMA)
- Participants
- 211 subjects6 studies
- Outcome
- Prevalence of aPL (aCL, anti-β2GPI, LA)
Methodological detailsPubMed search, January 1985 to December 2022, English-language studies, HUS cohorts excluded
- PubMed search, January 1985 to December 2022
- English-language studies
- HUS cohorts excluded
Pooled result
As reported in the abstract
Prevalence of aPL in renal TMA
Overall aPL prevalence (range 22-56)
24.4%
aCL (IgG/IgM) prevalence (range 3-27)
4.0%
Anti-β2GPI (IgG/IgM) prevalence (range 3-16)
4.0%
Lupus anticoagulant (LA) prevalence (range 13-25)
18.9%
Further pooled results
APS diagnosis
- APS diagnosed (range 11-29)
- 16.3%
Original publication
The estimated prevalence of antiphospholipid antibodies and criteria-antiphospholipid syndrome in subjects with renal thrombotic microangiopathy. Lupus. Published 20 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →